Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, Dirix L, Sweep FC, Span PN, Linn SC, Foekens JA, Sleijfer S, Berns EM, Jansen MP.
Ramirez-Ardila DE, et al. Among authors: look mp.
Breast Cancer Res Treat. 2013 May;139(1):39-49. doi: 10.1007/s10549-013-2529-7. Epub 2013 Apr 17.
Breast Cancer Res Treat. 2013.
PMID: 23592373